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A Corrigendum on
Advances in non-dopaminergic phar-
macological treatments of Parkinson’s
disease
by Stayte, S., and Vissel, B. (2014). Front.
Neurosci. 8:254. doi: 10.3389/fnins.2014.
00254
Figure 1 of the article by Stayte and
Vissel (2014) contained an error during
editing, which we now rectify. In the
original Figure 1, the blue arrows rep-
resenting the GABAergic projections to
the LGP originate from the cerebral cor-
tex. However, the blue arrows should be
originating from the striatum. We include
the updated version of Figure 1 with this
correction.
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FIGURE 1 | Basal ganglia dysfunction in PD. Diagram representing the
normal function of the basal ganglia (Left), the changes occurring in PD
(Right), and the site of primary action of therapeutic targets discussed in this
review (numbered). Arrows represent the major neurotransmitters of
glutamate (green), GABA (blue) and dopamine (red). Relative thickness of the
arrows indicates level of activity of neurotransmitter. SNpc, substantia nigra
pars compacta; SNr, substantia nigra reticulata; STN, subthalamic nucleus;
MGP, medial globus pallidus; LGP, lateral globus pallidus.
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